Enzogenol is extracted from New Zealand pine bark with a method that is ecologically sound, and effectively purifies the polyphenol compounds from the pine bark. The water-based extraction method does not rely on solvents or chemicals, and delivers a high antioxidant pine bark extract. Only pine bark and de-ionized water are used in the process.
Compositional analyses of Enzogenol have shown that the extract has a very high batch to batch consistency with approximately 84% PAC content and 1.5% taxifolin content with other polyphenols including catechin, astringenin (= piceatannol), quercetin, and several phenolic acids. Co-extracted carbohydrates are present at approximately 8.6%.
Research of Antioxidant Properties
Enzogenol was compared to other well known polyphenol extracts and antioxidants including Pinus pinaster (maritima) bark extract, grape seed and grape skin extracts, catechin and ascorbic acid . Antioxidant activities were measured at different pH values to represent the different pH environments of those of the digestive tract and blood stream.
Through independent testing labs, Enzogenol had the strongest antioxidant activity across the range of pHs as measured by superoxide radical scavenging ability using NBT and WST-1 assays, and the Oxygen Radical Absorbance Capacity (ORAC) assay.
Studies have been performed on its benefits for its anti-inflammatory properties, brain health including traumatic brain injury (TBI), cardiovascular health, and Glycemic control with stunning results. As a potent antioxidant, studies also assessed its promise in telomere expression and life span with extremely impressive results.
Nootropic Studies
In one of many studies of the effects of Enzogenol on brain function, Doctor Slobounov at Penn State Center for Sport Concussion, Pennsylvania State University tested student-athletes with concussion history assessing the feasibility of taking Enzogenol daily as a treatment modality in college-age athletes with a history of sports-related concussions.
After 6 weeks, EEG analyses revealed enhanced frontal-midline theta and decreased parietal theta power during brain loading with psychological tests indicating reduced mental fatigue when performing the brain challenging tasks. In contrast to the controls, the student-athletes receiving Enzogenol also reported experiencing lesser mental fatigue and reduced sleep problems
This demonstrated that Enzogenol can reduce brain fatigue during cognitive loading and has the potential to improve brain functioning in the chronic phase of concussion.
Glycemic Studies
It had been previously demonstrated that Enzogenol exhibits the ability to significantly improve postprandial glucose in healthy participants, especially those exhibiting monophasic glucose curve shapes indicative of poorer glycaemic control. Additionally, the percentage increment of postprandial glucose (%PG) and 2 h postprandial glucose (2hPG) were significantly reduced with Enzogenol® in healthy participants regardless of their glucose curve shapes. For example, in contrast to control (placebo), 50 mg of Enzogenol® significantly reduced %PG (p = 0.003) and 2hPG (p = 0.041), and at 400 mg an even higher reductions in %PG (p < 0.001) and 2hPG (p = 0.012) were observed.
This arguably makes Enzogenol® perhaps the most potent glucose control ingredient in the industry as such that it is so effective at such a low dose.
Further, the resultant reduction in 2hPG in healthy individuals implies the benefit of longer telomeres as the two are inversely correlated.
Animal studies
Mouse Longevity Trials
Two animal feeding trials were carried out at The University of Canterbury, Christchurch, New Zealand to investigate whether Enzogenol has an effect on lifespan. Results showed a significant increase in mean life span of 18.4% from 84.7 weeks in the control group to 100.3 weeks in the Enzogenol group (p<0.05). This increase in mean lifespan was remarkable considering that the feeding started at 52 weeks when the mice were already middle age.
Rat Telomere Trial
To further investigate the anti-aging properties of Enzogenol another animal feeding trial was carried out that analyzed telomere length in leukocytes. The results showed that the mice fed the Enzogenol had had significantly longer telomeres (40% longer) than the control group indicating a slowing of the age-related telomere shortening process.
The assumption that Enzogenol is effective at lower doses than studied has been demonstrated in follow up studies including the following (as stated by the CEO of the company that discovered and produces Enzogenol:
Therefore, the evidence from the research and validation from over four years of clinical use is sufficient to warrant confident product efficacy and our decision to move forward with the current formulation.
Our product, GenZogenol-R, contains Enzogenol along with other potent antioxidants that include pterostilbene and resveratrol, astaxanthin, quercetin and green tea extract along with lecithin.